

Expression of DNMT3A Gene in Adult Acute Myeloid Leukemia Patients

Thesis

Submitted for Fulfillment of Master Degree
in Internal Medicine

By

Dina Mohamed Abdou Mansour

M.B.B.ch, Faculty of Medicine –Ain Shams University

Under Supervision of

Prof. Dr. Inas Ahmed Hussein Asfour

Professor of Internal Medicine and Clinical Hematology

Faculty of Medicine–Ain Shams University

Prof. Dr. Hany Mohammed Abd-Allah Hegab

Professor of Internal Medicine and Clinical Hematology

Faculty of Medicine–Ain Shams University

Dr. Walaa Ali El-Salakawy

Assistant Professor of Internal Medicine and Clinical Hematology

Faculty of Medicine–Ain Shams University

Dr. Mohamed Tarif Hamza

Assistant Professor of Clinical Pathology

Faculty of Medicine–Ain Shams University

Dr. Alia Mohammed Saeed

Lecturer of Internal Medicine and Clinical Hematology

Faculty of Medicine–Ain Shams University

**Faculty of Medicine
Ain Shams University**

2018

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سبحانك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢



Acknowledgments

*First of all, I am deeply indebted to **Allah**, the Most Merciful and the most Gracious for the unlimited help, guidance, support, faith, blessings, and gifts and for everything.*

*I would like to express my deepest appreciation and gratitude to **Prof. Dr. Inas Ahmed Hussein Asfour**, Professor of Internal Medicine and Clinical Hematology, Faculty of Medicine-Ain Shams University, for her great support, close supervision and continuous encouragement throughout the whole work, it was a great honor to work under her supervision.*

*I stand in a great debt to **Dr. Hany Mohammed Abd-Allah Hegab**, Professor of Internal Medicine and Clinical Hematology, Faculty of Medicine-Ain Shams University, for his guidance, supervision through the whole study.*

*Special thanks and appreciation to **Dr. Walaa Ali El-Salakawy**, Assistant Professor of Internal Medicine and Clinical Hematology, Faculty of Medicine-Ain Shams University, for her active guidance and keen supervision which were of great help throughout this work.*

*Special thanks and tribute to **Dr. Mohamed Tarif Hamza**, Assistant Professor of Internal Medicine and Clinical Hematology, Faculty of Medicine-Ain Shams University, for the efforts and time he has devoted to accomplish this work.*

*My deepest appreciation to **Dr. Alia Mohammed Saeed**, Lecturer of Clinical Pathology, Faculty of Medicine-Ain Shams University, for her great support, close supervision and continuous encouragement throughout the whole work.*

Finally special thanks to all member of my Family, for their care and support throughout my life.

List of Contents

<i>Subject</i>	<i>Page No.</i>
List of Abbreviations.....	i
List of Tables.....	iii
List of Figures	v
Introduction	1
Aim of the Work.....	6
Review of Literature	
Acute Myeloid Leukemia (AML)	7
Cytogenetic Abnormalities in AML.....	32
Epigenetics	68
DNA Methyl Transferase (DNMT3A).....	90
Reactive oxygen species (ROS):	102
Patients and Methods.....	117
Results.....	134
Discussion	167
Summary	184
Conclusions and Recommendations	186
References	187
Arabic Summary	—

List of Abbreviations

<i>Abbrev.</i>	<i>Full-term</i>
AML	: Acute myeloid leukemia
APL	: Acute promyelocytic leukemia
Asx1	: Additional sex combs like-1
BCOR	: BCL6 Corepressor
biCEBPA	: Biallelic CEBPA mutation
CBF	: Core binding factor
CBF	: Core binding factor;
CD33	: Cluster of differentiation
CK-AML	: Complex karyotype
CN-AML	: Cytogenetically normal acute myeloid leukemia
CR	: Complete remission
DMRGM	: DNA-methylation regulatory gene mutations
DNMT3A	: DNA methyltransferase-3-alpha gene
DNMT3A^{WT}	: DNA methyltransferase-3-alpha gene wild type
EFS	: Event-free survival
ELN	: European Leukemia Net
FISH	: Fluorescence in situ hybridization
FLT3	: fms-related tyrosine kinase 3
Hb	: Hemoglobin
HDAC	: Histone deacetylase
HMA	: Hypomethylating agents
HSCT	: Hematopoietic stem cell transplantation
HSPC	: Hematopoietic stem and progenitor cells

IDH	: Isocitrate dehydrogenase
kmt2a	: Lysine methyltransferase 2A.
MK-AML	: Monosomal karyotype
MRD	: Minimal residual disease
ncRNA	: Non-coding RNA
NGS	: Next generation sequencing
NO	: Nitric oxide
OS	: Overall survival
PFS	: Progression-free survival
PLT	: Platelets
RNA-seq	: RNA Sequencing
RNS	: Reactive nitrogen species
ROC curve	: Receiver-operating characteristic curve
ROS	: Reactive oxygen species
RUNX1	: Runt-related transcription factor 1
SNP	: Single nucleotide polymorphism
TCGA	: The Cancer Genome Atlas
TET2	: Ten-Eleven Translocation 2
TLC	: Total leucocytic count
WGS	: Whole genome sequencing
α-KG	: Alpha ketoglutarate
2-HG	: 2-hydroxyglutarate
5-hmC	: 5-hydroxymethyl-cytosine
5-mC	: 5-methyl-cytosine

List of Tables

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
Table (1):	WHO Classification of Myelodysplastic syndromes (MDS)	9
Table (2):	Presenting symptoms of AML patient	20
Table (3):	WHO classification of AML.....	27
Table (4):	Expression of cell-surface and cytoplasmic markers for the diagnosis of AML and mixed phenotype acute leukemia.....	29
Table (5):	Prognostic classification of different genetic abnormalities in AML	35
Table (6):	APL variant translocations and response to ATRA	52
Table (7):	Different antioxidant elements.....	111
Table (8):	Patients characteristics	135
Table (9):	Percentages of different CD markers expression by immunophenotyping in the cohort.	139
Table (10):	Agreement (sensitivity, specificity) for different parameters to diagnose mutated cases cutoff point.....	145
Table (11):	Comparison between the two studied groups regarding level of expression	147
Table (12):	Comparison between patients having mutant DNMT3a allele versus those lacking a mutations with respect to demographic as well as clinical parameters.	149
Table (13):	Relationship between DNMT3A mutational status and different FAB subtypes in group I.....	150
Table (14):	Relationship between DNMT3A mutational status with CD34 andCD117.....	151

Table (15): Comparison DNMT3A expression and NO level before and after treatment in relation to DNMT3A mutational status.	151
Table (16): Relationship between DNMT3A mutational status and treatment outcome	155
Table (17): Comparison between low and high DNMT3a gene expressors with respect to their demographics as well as clinical data.	157
Table (18): Relationship between levels of gene expression and FAB classification.....	159
Table (19): Comparison between levels of DNMT3A gene expression and NO level before and after treatment.	160
Table (20): Comparison between the two studied groups according to DNMT3A expression and No. level before and after treatment.	161
Table (21): Multivariate analysis logistic regression for DNMT3A mutation.....	164
Table (22): Comparison of overall survival in relation to DNMT3A mutational status.....	165
Table (23): Assessment of the overall survival in relation to Level of gene expression.....	166

List of Figures

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
Figure (1):	Blood cell development. A blood stem cell goes through several steps to become a red blood cell, platelet, or white blood cell.	7
Figure (2):	The two-hit model of AML.	33
Figure (3):	Asx11, bcor, dnmt3a, idh1, idh2, kmt2a (mll), kras, nras, phf6, runx1, tet2, tp53, and wt1 direct and indirect effect on dna transcription.	46
Figure (4):	Flow chart for the therapy of newly diagnosed (AML).....	49
Figure (5):	Algorithm of treating newly diagnosed patients with APL	51
Figure (6):	Epigenetic mechanisms	70
Figure (7):	Tumor-genesis represents both genetic and epigenetic alterations.	71
Figure (8):	Transcription blocking.....	74
Figure (9):	Mechanisms of epigenetic regulation	77
Figure (10):	Inhibition of ten-eleven translocation (TET)-mediated DNA demethylation processes.....	87
Figure (11):	Domain architecture of DNA methyltransferase 1 (DNMT1), DNMT3A1, DNMT3A2, DNMT3B and DNMT3-like (DNMT3L) and major DNMT3A.....	90
Figure (12):	The two types of DNA methylation.	91
Figure (13):	DNMT3A mutation allele and gene dosage	96
Figure (14):	ROS/RNS, functions and impacts	104

Figure (15): Principle of TaqMan probes in quantitative Real Time PCR	127
Figure (16): Percentages of different FAB subtypes	139
Figure (17): Percentages of various cytogenetic risk groups.....	140
Figure (18): Percentages of different treatment outcomes amongst cases of the study.....	141
Figure (19): Percentages of wild type and mutantDNMT3A gene in AML patients of the study.	142
Figure (20): Comparison between DNMT3A gene expression in group 1 and group 2.....	143
Figure (21): DNMT3A mRNA expression in patient and control groups by real time PCR.	143
Figure (22): Comparison between two groups as regards NO level at diagnosis.	144
Figure (23): ROC for level of gene expression associated with gene mutations.	146
Figure (24): Comparison between the study groups regarding DNMT3a mRNAtranscript levels.	147
Figure (25): Comparison between mutated and un-mutated groups as regard DNMT3a expression before treatment.	153
Figure (26): Comparison between mutated and un-mutated groups as per DNMT3a expression after treatment.	153
Figure (27): Comparison between mutated and un-mutated groups as per NO levels before treatment.	154
Figure (28): Comparison between mutated and un-mutated groups as per NO levels after treatment.	154
Figure (29): Comparison between whole cohort patients as per DNMT3a expression before and after treatment.	163

Figure (30):	Comparison between whole cohort patients as per NO levels before and after treatment.	163
Figure (31):	Kaplan-Meier survival curve for overall survival...	164
Figure (32):	Kaplan-Meier survival curve for overall survival in relation to DNMT3A mutation.....	165
Figure (33):	Kaplan-Meier curve of the overall survival in relation to the level of gene expression.....	166

Abstract

Background

Acute Myeloid Leukemia (AML) is one of the most lethal hematological malignancies in the whole world, so continuous searching for modalities of diagnosis, treatment and prognosis is one of the continuous challenges in modern science. DNMT3A gene (DNA methyl transferase 3a) a member of epigenetic modifiers family which have such a significant role in DNA methylation and the cellular apoptosis and leukomogenesis.

Aim of the work

To Asses DNMT3A gene in newly diagnosed adult acute myeloid leukemia patient.

Subjects and Methods

A total of 45 patients with AML were included in the study. They were subjected to detailed medical, full clinical and hematological examination, and laboratory investigations including; CBC, CRP, peripheral blood smear for blasts, Bone marrow aspirate and cytogenetics.

Results

The most commonly found within the patient's pool was high prevalence of DNMT3A expression in AML M4-M5 subtype according to FAB classification (French and British classification). DNMT3A gene expression was significantly associated with lower response to treatment by conventional induction chemotherapy regemin (3+7), Lower overall survival (O.S) and progression free survival (P.F.S).

Conclusions/interpretation: DNMT3A gene should be included in the preliminary work up of AML patients as a prognostic factor.

Key words: DNMT3A, AML, FAB, CRP, O.S, P.F.S.

Introduction

*A*cute myeloid leukemia (AML) is an aggressive malignancy of the bone marrow characterized by uncontrolled proliferation of immature myeloid lineage cells. This type of cancer usually gets worse quickly if it is not treated. It is the most common type of acute leukemia in adults (*American Cancer Society, 2015*).

AML is not a single disease. It is the name given to a group of leukemia that develops in the myeloid cell line in the bone marrow. Some years ago doctors from America, France and Britain decided to classify AML into eight different sub-types based on the appearance of the leukemic cells under the microscope. Each sub-type provides information on the type of blood cell involved and the point at which it stopped maturing properly in the bone marrow. This is known as the French-American-British (FAB) classification system (*Alvi et al., 1990*).

The current World Health Organization classification system for AML uses additional information, obtained from more specialized laboratory techniques, like genetic studies, to classify AML more precisely. This information also provides more reliable information regarding the likely course (prognosis), of a particular subtype of AML, and the best way to treat it.

The most important factor in predicting prognosis in AML is the genetic make-up of the leukemic cells (*Byrd et al., 2002*). Certain cytogenetic changes are associated with a more favourable prognosis than others. This means that they are more likely to respond well to treatment, and may even be cured. Favourable cytogenetic changes include: a translocation between chromosome 8 and 21 t(8;21), inversion of chromosome 16; inv(16) and a translocation between chromosome 15 and 17; t(15;17) (*Haferlach et al., 2003*). Other cytogenetic changes are associated with an average or intermediate prognosis, while others still are associated with a poor, or unfavourable prognosis. It is important to note that in most cases of AML, neither ‘good’ or ‘bad-risk’ cytogenetic changes are found. People with ‘normal’ cytogenetics are also regarded as having an average prognosis (*Renneville et al., 2013*).

Recent advances in the research of acute myeloid leukemia (AML), especially the identification of novel genetic mutations, have enabled hematologists to stratify this heterogeneous disease entity into distinct subtypes beyond the scopes of cyto-morphology and cytogenetics. The progress not only brings insight into the pathogenesis of AML but also helps refine the treatment strategies for this group of patients. Along with the development of whole genome sequencing, it is probable that the major genetic

aberrations have been almost completely identified (*Gaidzik et al., 2013*). The next stage is to clarify the consequence of these molecular alterations, especially for the newly identified molecules. Mutations in several newly identified genes, such as TET2 and IDH1/2, lead to the aberrant hypermethylation signature in AML cells (*Yin et al., 2004*). Collectively, these recent findings strongly suggest a link between recurrent genetic alterations and aberrant epigenetic regulation, resulting in abnormal DNA methylation statuses in myeloid malignancies.

The DNA methyltransferase 3A (DNMT3A) gene mutation is identified by whole-genome sequencing in patients with acute myeloid leukemia (AML). DNMT3A encodes for the enzyme DNA (cytosine-5) methyltransferase 3A and belongs to the family of other methyltransferases. These enzymes are involved in adding methyl groups to the cytosine residue of CpG dinucleotides and thus play an important role in epigenetic regulation of genes (*Cagnetta et al., 2014*), but the mechanism of DNMT3A mutation - associated leukemogenesis was still unknown. Mutations in DNMT3A are quite common in AML, occurring in approximately 20% of patients (*Hartmann et al., 2009*). The most common mutation is a substitution of the amino acid arginine at position 882 (R882) (*Shah, 2011*). DNMT3A mutations often co-occur with FLT3 ITD, NPM1, IDH1, and